PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 351-375 of 411

  • PI3K-IN-28
    Cat. No.
    A79841

    PI3K-IN-28

    PI3K-IN-28 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), showcasing significant potency in inhibiting its activity. With half-maximal inhibitory concentration (IC50) values of 5.8, 2.3, and 7.9 µM, PI3K-IN-28 demonstrates reduced toxicity in MCF-10a cell lines and a selectivity index (SI) of 39, highlighting its potential for anticancer applications. This compound serves as a promising lead for further development of targeted therapeutics in cancer research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Dezapelisib
    Cat. No.
    A79842

    Dezapelisib

    Synonyms: INCB040093

    Dezapelisib is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ) that demonstrates significant antitumor activity. This compound is primarily utilized in research focused on relapsed or refractory B-cell lymphomas, making it a valuable tool for understanding the therapeutic potential of targeted PI3Kδ inhibition in hematological malignancies. Its mechanism of action contributes to the modulation of cell proliferation and survival pathways, offering insights into cancer treatment strategies.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • PI3K-IN-38
    Cat. No.
    A79843

    PI3K-IN-38

    PI3K-IN-38 is an orally active inhibitor of phosphoinositide 3-kinase (PI3K), with an IC50 of 0.541 µM for PI3K-α. This compound demonstrates significant anticancer and anti-inflammatory properties, effectively inhibiting tumor growth in vivo. Its selective modulation of the PI3K pathway makes it a valuable tool for research into cancer therapies and inflammatory diseases.

    1 mg
    $65.00
    5 mg
    $150.00
    All 6 sizes
  • NVP-CLR457
    Cat. No.
    A79844

    NVP-CLR457

    NVP-CLR457 is a potent pan-class I PI3K inhibitor that exhibits oral bioavailability and a favorable pharmacokinetic/pharmacodynamic relationship. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. NVP-CLR457 is suitable for studies focused on the roles of PI3K signaling in various cancer types and therapeutic resistance mechanisms.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • PI3Kα-IN-22
    Cat. No.
    A79845

    PI3Kα-IN-22

    PI3Kα-IN-22 is a potent and selective inhibitor of the PI3KαH1047R mutant, demonstrating an IC50 of 1 nM in the pAKT T47D AlphaLISA assay. This orally active compound has shown the ability to induce tumor regressions in the HCC1954 mouse model, making it a valuable tool for studying PI3Kα-related pathways in cancer research and therapeutic development. Its specificity and efficacy support its use in investigations aimed at targeting PI3Kα-driven malignancies.

    Out of stock

    All 3 sizes
  • TGX-155
    Cat. No.
    A79846

    TGX-155

    Synonyms: AZ12649385

    TGX-155 is a selective inhibitor of PI3Kβ, a key enzyme involved in the phosphoinositide 3-kinase signaling pathway. This compound exhibits significant antithrombotic activity, making it a potential therapeutic agent for the treatment of thrombotic disorders. Its application in research may enhance the understanding of PI3Kβ-related mechanisms in cardiovascular biology and drug development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-51
    Cat. No.
    A79847

    PI3K-IN-51

    PI3K-IN-51 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, exhibiting IC50 values below 500 nM for the p120γ and p110δ/p85α isoforms. This compound is crucial for investigating the role of PI3K in cellular processes such as growth, proliferation, and survival. It has applications in cancer research and other fields where PI3K signaling plays a significant role in disease progression.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PF-376304
    Cat. No.
    A79848

    PF-376304

    PF-376304 is an orally active, non-specific class I phosphoinositide 3-kinase (PI3K) inhibitor, exhibiting an IC50 of 0.197 μM against PI3Kγ. This compound is shown to induce dose-dependent metabolic disorders related to glucose and lipid metabolism in animal models, with rapid lethality observed at elevated doses. Additionally, metabolic abnormalities induced at lower doses demonstrate self-reversibility. PF-376304 is valuable for research into metabolic and inflammatory diseases, providing insights into PI3K involvement in these pathological conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PROTAC PI3K/110β degrader-1
    Cat. No.
    A79849

    PROTAC PI3K/110β degrader-1

    PROTAC PI3K/110β degrader-1 is a targeted protein degradation tool designed to selectively degrade the PI3K/110β protein. This reagent employs a PROTAC mechanism, linking an inhibitor of PI3K/110β with an E3 ligase ligand to facilitate ubiquitination and degradation. Its primary biological activity is to reduce levels of PI3K/110β, making it a valuable resource for studies exploring PI3K-related signaling pathways and their implications in cancer research and other diseases.

    Out of stock

    All 3 sizes
  • (R)-IHMT-PI3Kδ-372
    Cat. No.
    A79850

    (R)-IHMT-PI3Kδ-372

    (R)-IHMT-PI3Kδ-372 is a selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway, exhibiting an IC50 of 19 nM. This compound is primarily utilized in research related to chronic obstructive pulmonary disease (COPD), where modulation of the PI3Kδ signaling pathway may provide therapeutic insights. Its potency and specificity make it a valuable tool for investigating PI3Kδ's role in inflammatory and immune responses.

    1 mg
    $25.00
    5 mg
    $55.00
    All 6 sizes
  • FD2056
    Cat. No.
    A79852

    FD2056

    FD2056 is a potent, orally active inhibitor of the phosphoinositide 3-kinase (PI3K) family, with specific inhibition of PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, exhibiting IC50 values of 0.30, 0.80, 1.10, and 0.42 nM, respectively. This compound also targets cyclin-dependent kinases, inhibiting CDK2-CyclinA2 and CDK4-CyclinD3 with IC50 values of 115.95 nM and 2782.15 nM. FD2056 demonstrates significant antiproliferative effects in breast cancer cell lines, with IC50 values of 1.06 μM for MDA-MB-231, 0.04 μM for MDA-MB-468, and 1.40 μM for MCF-7 cells. Additionally, FD2056 promotes apoptosis in cancer cells and effectively inhibits tumor growth.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kδ-IN-3
    Cat. No.
    A79853

    PI3Kδ-IN-3

    PI3Kδ-IN-3 is a selective inhibitor of the PI3Kδ isoform, exhibiting an IC50 of 9 nM. This compound effectively inhibits B cell function, making it a valuable tool for studying immune responses and related disorders. With favorable pharmacokinetic properties, PI3Kδ-IN-3 is suitable for in vitro and in vivo research applications in the field of immunology and cancer therapeutics.

    1 mg
    $70.00
    5 mg
    $160.00
    All 7 sizes
  • PI3Kα-IN-13
    Cat. No.
    A79854

    PI3Kα-IN-13

    PI3Kα-IN-13 is a selective inhibitor of PI3Kα, demonstrating an IC50 value of 2.5 nM. This compound effectively induces apoptosis in tumor cells, significantly inhibiting cancer cell proliferation across various cell lines, including MCF-7 (IC50: 0.75 μM), HCT-116 (IC50: 3.79 μM), MDA-MB-231 (IC50: 13.71 μM), and SW620 (IC50: 9.85 μM). Additionally, PI3Kα-IN-13 reduces tumor cell colony formation, migration, and invasion, making it a valuable tool for cancer research and therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kγ inhibitor 6
    Cat. No.
    A79855

    PI3Kγ inhibitor 6

    PI3Kγ Inhibitor 6 is a selective inhibitor of the phosphoinositide 3-kinase gamma (PI3Kγ) enzyme. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory and autoimmune diseases. Its inhibition of PI3Kγ can help elucidate the signaling pathways involved in various pathological conditions, providing insights into potential therapeutic strategies.

    5 mg
    $75.00
    10 mg
    $110.00
    All 6 sizes
  • PI3Kδ-IN-17
    Cat. No.
    A79857

    PI3Kδ-IN-17

    PI3Kδ-IN-17 is a highly selective inhibitor of PI3Kδ, exhibiting an IC50 of 2.82 nM. This compound demonstrates significant anti-proliferative effects in SU-DHL-6 cells, with an IC50 value of 0.035 μM. PI3Kδ-IN-17 is valuable for research applications focusing on cancer biology and the modulation of cell proliferation pathways.

    Out of stock

    All 3 sizes
  • PX-866-17OH
    Cat. No.
    A79858

    PX-866-17OH

    PX-866-17OH is a pan-isoform inhibitor of phosphoinositide 3-kinases (PI3K) that exhibits IC50 values of 14, 57, 131, and 148 nM against PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. Its primary action as a metabolite of PX-866 (Sonolisib) makes it a valuable tool in the study of PI3K signaling pathways. PX-866-17OH has potential applications in cancer research and therapeutic development, particularly in contexts where PI3K signaling contributes to tumor growth and survival.

    1 mg
    $185.00
    5 mg
    $575.00
    All 3 sizes
  • IMM-H012
    Cat. No.
    A79859

    IMM-H012

    IMM-H012 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), exhibiting an IC50 of 0.80 nM for PI3Kα. This compound demonstrates significant antitumor activity when used in combination with [177Lu]Lu-P4, showing synergistic effects against stomach and lung cancers. It is a valuable tool for researchers investigating PI3K signaling pathways and their implications in cancer therapeutics.

    Out of stock

    All 3 sizes
  • ML-220
    Cat. No.
    A79860

    ML-220

    ML-220 is a selective PI3K modulator that plays a crucial role in the regulation of cellular signaling pathways. This compound has demonstrated significant biological activity in the context of neoplasms and infectious diseases, making it a valuable tool for research applications aimed at understanding tumor biology and host-pathogen interactions. Its mechanism of action on the PI3K pathway positions ML-220 as a promising candidate for further investigation in therapeutic development.

    Out of stock

    All 3 sizes
  • PI3K-IN-50
    Cat. No.
    A79861

    PI3K-IN-50

    PI3K-IN-50 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), known for its ability to interfere with key signaling pathways involved in cell growth and metabolism. This compound demonstrates potent inhibitory activity against PI3K, making it valuable for research focused on cancer, metabolic disorders, and other diseases associated with dysregulated PI3K signaling. Its utility in studying PI3K-related biological processes makes it an important tool for investigating therapeutic strategies targeting this pathway.

    Out of stock

    All 3 sizes
  • HM5023507
    Cat. No.
    A79862

    HM5023507

    HM5023507 is a selective inhibitor of PI3Kδ and PI3Kγ, exhibiting IC50 values of 4 μM and 5 μM, respectively, while showing minimal activity against PI3Kα and PI3Kβ. This compound effectively attenuates PI3Kδ/γ signaling in human basophils and suppresses the activation, function, and cytokine production of human B and T cells, impacting Th17 differentiation in CD4 T cells. In vivo studies demonstrate that HM5023507 can inhibit collagen-induced inflammatory responses in rat models, making it a valuable tool for research into inflammatory diseases, particularly rheumatoid arthritis.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-11
    Cat. No.
    A79863

    PI3Kα-IN-11

    PI3Kα-IN-11 is a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα), demonstrating significant efficacy in interrupting the PI3K signaling pathway. This compound exhibits potent anticancer activity, making it a valuable tool for research on tumorigenesis and cancer therapy. Its application spans in vitro studies to evaluate the role of PI3Kα in cancer proliferation and progression, contributing to the development of targeted cancer treatments.

    1 mg
    $65.00
    5 mg
    $160.00
    All 7 sizes
  • PI3Kγ inhibitor 7
    Cat. No.
    A79864

    PI3Kγ inhibitor 7

    PI3Kγ inhibitor 7 is a selective inhibitor targeting the phosphoinositide 3-kinase gamma isoform (PI3Kγ), exhibiting an IC50 value of 3.42 nM for this target, while showing significantly higher IC50 values for PI3Kα, PI3Kβ, and PI3Kδ. This compound demonstrates notable antitumor activity, making it suitable for cancer research applications. Additionally, PI3Kγ inhibitor 7 contains an alkyne functional group, enabling its use in click chemistry reactions, specifically copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • 17β-Hydroxywortmannin
    Cat. No.
    A79865

    17β-Hydroxywortmannin

    Synonyms: Wortmannin-17β-ol

    17β-Hydroxywortmannin is a potent inhibitor of phosphatidylinositol-3-kinase (PI3K) with an impressive IC50 of 0.5 nM. This compound effectively suppresses osteoclast resorption, displaying an IC50 of 10 nM, and exhibits notable antitumor activity. It is valuable in research applications focused on cancer biology and bone metabolism.

    0.5 mg
    $105.00
    1 mg
    $190.00
    All 3 sizes
  • PI3K-IN-23
    Cat. No.
    A79866

    PI3K-IN-23

    PI3K-IN-23 is a selective PI3K activator that enhances glucose uptake with an EC50 value of 7.00 μM. This compound serves as a versatile click chemistry reagent due to its alkyne functionality, enabling efficient copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its applications extend to metabolic research and biochemical studies exploring PI3K pathways.

    Out of stock

    All 3 sizes
  • PI3K-IN-49
    Cat. No.
    A79867

    PI3K-IN-49

    PI3K-IN-49 is a selective phosphoinositide 3-kinase (PI3K) inhibitor. It exhibits significant antiproliferative effects in T-47D and SKBR3 cell lines, making it a valuable tool for cancer research. This compound can be utilized to investigate PI3K signaling pathways and their role in tumor growth and progression.

    Out of stock

    All 3 sizes

Items 351-375 of 411

Added to your cart

View Cart Checkout

    Loading...